Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Sunday, June 21, 2026 1 min read

Key Takeaway: Definium Therapeutics is set to discuss the topline results from its Phase 3 Emerge Study focused on Major Depressive Disorder. The discussion is scheduled for June 22, 2026. This event marks a significant milestone in the company's research efforts in this area.